Figure 3
From: A novel tissue model for angiogenesis: evaluation of inhibitors or promoters in tissue level
Sorafenib inhibits angiogenesis and Tongxinluo capsule promotes angiogenesis in the TMA.
(a1) The representative images of lung tissue blood vessels in the untreated group on the 9th day; a2–a4: lung tissue vessels in the sorafenib-treated group on the 9th day; (a2) 20 nM, (a3) 100 nM, (a4) 500 nM. Vessels grew normally in control group; vessels in the sorafenib (20, 100, 500 nM)-treated group exhibited the slowly increase compared with the control group. Bar = 500 μm. (b1) The representative images of lung tissue blood vessels in the untreated group on the 5th day; b2–b4: lung tissue vessels in the sorafenib-treated group on the 9th day; (b2) 1 h serum, (b3) 2 h serum, (b4) 3 h serum. (c) Quantification of microvessels numbers in sorafenib treated group with the increased days. (n = 3) (d) Quantification of vessels length in sorafenib treated group along with the time prolonged. Data were expressed as mean values ± SEM. (n = 7). *P < 0.05, **P < 0.01 versus the control group. (e) Quantification of microvessels numbers in Tongxinluo capsule treated group with the increased days. (n = 3) (f) Quantification of vessels length in Tongxinluo capsule treated group along with the time prolonged. Data were expressed as mean values ± SEM. (n = 7). *P < 0.05, **P < 0.01 versus the control group.
